There were no big surprises for Gilead’s ($GILD) $11 billion hepatitis C drug sofosbuvir at today’s FDA panel review. The therapy, which promises to help create an entirely new standard of care for the millions of people afflicted with the virus, won a clear endorsement from agency experts. And now it’s likely headed for a […]
↧